In conclusion, our findings postulate Tie1 and Tie2 ligands as potential biomarkers of states of low disease activity and remission in patients with SLE and identified a new molecular mechanism of endothelial destabilization mediated by type I IFN and Tie2 signalling pathways, which may contribute to cardiovascular events in patients with SLE. Here, TIE1 is linked to systemic lupus erythematosus.